OliX Pharmaceuticals (XKRX:226950) Debt-to-Equity : 2.20 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is OliX Pharmaceuticals Debt-to-Equity?

OliX Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩17,759 Mil. OliX Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩21,434 Mil. OliX Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₩17,849 Mil. OliX Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2024 was 2.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for OliX Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

XKRX:226950' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.32 Max: 2.2
Current: 2.2

During the past 11 years, the highest Debt-to-Equity Ratio of OliX Pharmaceuticals was 2.20. The lowest was 0.01. And the median was 0.32.

XKRX:226950's Debt-to-Equity is ranked worse than
94.68% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:226950: 2.20

OliX Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for OliX Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OliX Pharmaceuticals Debt-to-Equity Chart

OliX Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.32

2.00

0.67

0.79

2.20

OliX Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.79	1.29	1.85	2.99	2.20

Competitive Comparison of OliX Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, OliX Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OliX Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OliX Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where OliX Pharmaceuticals's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

OliX Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

OliX Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17758.638	+	21433.784)	/	17848.89
	=	2.20

OliX Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17758.638	+	21433.784)	/	17848.89
	=	2.20

OliX Pharmaceuticals (XKRX:226950) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

OliX Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of OliX Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

OliX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226

Website

http://www.olixpharma.com

OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals Headlines

No Headlines